This pharmaceutical executive has Trump’s ear
David Ricks, CEO of the Indiana drugmaker, has cut deals with the president to slash prices and build American. Trump has showered him with praise.
Today's Liberal News
By David Lim
This pharmaceutical executive has Trump’s ear
David Ricks, CEO of the Indiana drugmaker, has cut deals with the president to slash prices and build American. Trump has showered him with praise.
This pharmaceutical executive has Trump’s ear
David Ricks, CEO of the Indiana drugmaker, has cut deals with the president to slash prices and build American. Trump has showered him with praise.
This pharmaceutical executive has Trump’s ear
David Ricks, CEO of the Indiana drugmaker, has cut deals with the president to slash prices and build American. Trump has showered him with praise.
This pharmaceutical executive has Trump’s ear
David Ricks, CEO of the Indiana drugmaker, has cut deals with the president to slash prices and build American. Trump has showered him with praise.
This pharmaceutical executive has Trump’s ear
David Ricks, CEO of the Indiana drugmaker, has cut deals with the president to slash prices and build American. Trump has showered him with praise.
This pharmaceutical executive has Trump’s ear
David Ricks, CEO of the Indiana drugmaker, has cut deals with the president to slash prices and build American. Trump has showered him with praise.
This pharmaceutical executive has Trump’s ear
David Ricks, CEO of the Indiana drugmaker, has cut deals with the president to slash prices and build American. Trump has showered him with praise.
This pharmaceutical executive has Trump’s ear
David Ricks, CEO of the Indiana drugmaker, has cut deals with the president to slash prices and build American. Trump has showered him with praise.
This pharmaceutical executive has Trump’s ear
David Ricks, CEO of the Indiana drugmaker, has cut deals with the president to slash prices and build American. Trump has showered him with praise.
Trump’s drug-pricing deals won’t benefit most Americans today. They could over time.
Most Americans likely will not benefit immediately from efforts to lower prescription prices. Administration officials expect effects to spread as markets are reshaped.
Trump’s drug-pricing deals won’t benefit most Americans today. They could over time.
Most Americans likely will not benefit immediately from efforts to lower prescription prices. Administration officials expect effects to spread as markets are reshaped.
Trump’s CMS touts $12B savings from Medicare drug price negotiations
The second round of Inflation Reduction Act negotiation prices, which includes 15 brand-name drugs, will kick into effect in 2027.
Trump’s CMS touts $12B savings from Medicare drug price negotiations
The second round of Inflation Reduction Act negotiation prices, which includes 15 brand-name drugs, will kick into effect in 2027.
Trump’s CMS touts $12B savings from Medicare drug price negotiations
The second round of Inflation Reduction Act negotiation prices, which includes 15 brand-name drugs, will kick into effect in 2027.
Trump’s CMS touts $12B savings from Medicare drug price negotiations
The second round of Inflation Reduction Act negotiation prices, which includes 15 brand-name drugs, will kick into effect in 2027.
Trump’s CMS touts $12B savings from Medicare drug price negotiations
The second round of Inflation Reduction Act negotiation prices, which includes 15 brand-name drugs, will kick into effect in 2027.
Trump’s CMS touts $12B savings from Medicare drug price negotiations
The second round of Inflation Reduction Act negotiation prices, which includes 15 brand-name drugs, will kick into effect in 2027.
Trump’s CMS touts $12B savings from Medicare drug price negotiations
The second round of Inflation Reduction Act negotiation prices, which includes 15 brand-name drugs, will kick into effect in 2027.
Pfizer, Trump strike drug pricing deal
The deal is a victory for Trump who has pressured drugmakers to voluntarily comply with his policy priorities. If not, they will likely face regulation or high tariffs.
Pfizer, Trump strike drug pricing deal
The deal is a victory for Trump who has pressured drugmakers to voluntarily comply with his policy priorities. If not, they will likely face regulation or high tariffs.
The Trump administration’s favored tactic to force companies to act
President Donald Trump is relying on drugmakers to lower U.S. prices on their own, but he might get less than he bargained for.
Pfizer, Trump strike drug pricing deal
The deal is a victory for Trump who has pressured drugmakers to voluntarily comply with his policy priorities. If not, they will likely face regulation or high tariffs.
The Trump administration’s favored tactic to force companies to act
President Donald Trump is relying on drugmakers to lower U.S. prices on their own, but he might get less than he bargained for.
Pfizer, Trump strike drug pricing deal
The deal is a victory for Trump who has pressured drugmakers to voluntarily comply with his policy priorities. If not, they will likely face regulation or high tariffs.
The Trump administration’s favored tactic to force companies to act
President Donald Trump is relying on drugmakers to lower U.S. prices on their own, but he might get less than he bargained for.
Pfizer, Trump strike drug pricing deal
The deal is a victory for Trump who has pressured drugmakers to voluntarily comply with his policy priorities. If not, they will likely face regulation or high tariffs.
The Trump administration’s favored tactic to force companies to act
President Donald Trump is relying on drugmakers to lower U.S. prices on their own, but he might get less than he bargained for.
The Trump administration’s favored tactic to force companies to act
President Donald Trump is relying on drugmakers to lower U.S. prices on their own, but he might get less than he bargained for.
Pfizer, Trump strike drug pricing deal
The deal is a victory for Trump who has pressured drugmakers to voluntarily comply with his policy priorities. If not, they will likely face regulation or high tariffs.